SLGL News and Press, Sol-Gel Technologies Ltd. From 07/27/21

TWYNEO ® , a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038 Un...

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quart...

Sol-Gel Technologies (SLGL) and Galderma has signed two exclusive five-year license agreements for the commercialization of Epsolay and Twyneo in the United States. Under the pact, Galderma has an exclusive license to commercialize Sol-Gel's advanced investigational drug products using Sol-Ge...

Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal model Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients ...

- Upfront and approval payments of up to $15 million - Tiered royalties ranging from mid- to high-teen percentage of net sales - Sol-Gel option to regain commercialization rights 5 years following first commercialization Sol-Gel Technologies, Ltd. (NASDAQ: SLGL),...

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases...

Sol-Gel Technologies (SLGL): Q1 GAAP EPS of $0.18 beats by $0.63.Revenue of $0.7M (-79.8% Y/Y) misses by $0.97M.Press Release For further details see: Sol-Gel Technologies EPS beats by $0.63, misses on revenue

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ® - EPSOLAY PDUFA goal date was set for April 26, 2021. Awaiting FDA ’s pre-approval inspection ...

Gainers: Tian Ruixiang (TIRX) +54%.Vaxart (VXRT) +51%.RiceBran Technologies (RIBT) +47%.Aldeyra Therapeutics (ALDX) +31%.NetSol Technologies (NTWK) +30%.First Choice Bancorp (FCBP) +28%.TrueBlue (TBI) +26%.Brooklyn ImmunoTherapeutics (BTX) +23%.Big Rock Partners Acquisition (BRPA) +23%.T...

Sol-Gel Technologies ([[SLGL]] -21.1%) has shed more than a fifth in value after announcing that the company received no notification from the FDA regarding its marketing application for EPSOLAY (benzoyl peroxide) 5% topical cream for adults with Inflammatory lesions of rosacea.However, ...